Provided herein are tissue grafts, and in particular human placenta-derived tissue grafts and methods and articles for the manufacture and use thereof.

Provided herein are tissue grafts, and in particular human placenta-derived tissue grafts and methods and articles for the manufacture and use thereof.

The present disclosure provides methods for treating acute wounds and improving outcomes by applying to an acute wound a skin substitute that is an organotypic human skin equivalent comprising NIKS cells. In certain embodiments, the closed wound has improved vascularity, improved pigmentation, decreased thickness, decreased pain, increased pliability, increased surface area, decreased stiffness, decreased itching, improved color, or any combination thereof, as assessed by an observer or by the subject, as compared to an autograft or another skin substitute.

The present disclosure provides methods for treating acute wounds and improving outcomes by applying to an acute wound a skin substitute that is an organotypic human skin equivalent comprising NIKS cells. In certain embodiments, the closed wound has improved vascularity, improved pigmentation, decreased thickness, decreased pain, increased pliability, increased surface area, decreased stiffness, decreased itching, improved color, or any combination thereof, as assessed by an observer or by the subject, as compared to an autograft or another skin substitute.

There is provided a composition for forming an artificial skin that can shorten the cross-linking time while maintaining excellent application performance and coating performance.

A composition for forming an artificial skin of the present disclosure comprises a first agent and a second agent, wherein the first agent comprises: (a) a polymer A composed of one or more organopolysiloxanes containing at least two carbon-carbon double bonds or at least one carbon-carbon triple bond in the molecule; (b) a polymer B composed of one or more organopolysiloxanes containing at least two Si—H units in the molecule; and (c) a silicone having a viscosity of 1.5 mPa.Math.s or less at 25° C., and wherein the second agent comprises a catalyst that promotes cross-linking of the polymer A and the polymer B.

There is provided a composition for forming an artificial skin that can shorten the cross-linking time while maintaining excellent application performance and coating performance.

A composition for forming an artificial skin of the present disclosure comprises a first agent and a second agent, wherein the first agent comprises: (a) a polymer A composed of one or more organopolysiloxanes containing at least two carbon-carbon double bonds or at least one carbon-carbon triple bond in the molecule; (b) a polymer B composed of one or more organopolysiloxanes containing at least two Si—H units in the molecule; and (c) a silicone having a viscosity of 1.5 mPa.Math.s or less at 25° C., and wherein the second agent comprises a catalyst that promotes cross-linking of the polymer A and the polymer B.

Provided is a cell structure including: a connective tissue structure; and an epithelial structure placed on the connective tissue structure, in which the connective tissue structure contains a fragmented extracellular matrix component and first cells including mesenchymal cells, at least a part of the fragmented extracellular matrix component is placed between the first cells, and the epithelial structure contains epithelial cells.

The present invention relates to a novel acellular artificial skin substitute or scaffolds comprising biopolymer and bioactive components and the process of preparing said artificial skin substitute. The novel artificial foam-based skin substitute scaffold of the present invention addresses the problems in the prior art by providing a biocompatible, biodegradable, Non-immunogenic, non-irritant and a cost-effective scaffold.

The present invention relates to a novel acellular artificial skin substitute or scaffolds comprising biopolymer and bioactive components and the process of preparing said artificial skin substitute. The novel artificial foam-based skin substitute scaffold of the present invention addresses the problems in the prior art by providing a biocompatible, biodegradable, Non-immunogenic, non-irritant and a cost-effective scaffold.

A bioactive suspension derived from freshly disaggregated tissue is provided, as well as related methods of formulation and use. The bioactive suspension may comprise a cell-free supernate derived from epidermal and dermal tissue that has been enzymatically and mechanically disaggregated, then separated, and which may contain tissue regeneration factors known to speed healing. The bioactive suspension may further comprise genetically-modified treatment cells, wild type cells, or both, and may be combined with one or more scaffolding elements to form a bioactive suspension combination product suitable for treatment of a cutaneous defect. Synthetic bioactive suspensions and bioactive suspension combination products are also provided.